Clinical Relevance of Elevated Levels of Serum Soluble Interleukin-2 Receptor alpha (sIL-2Ra) in Patients with Non-Hodgkin’s Lymphoma
0
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Levels of soluble interleukin-2 receptor alpha (sIL-2Ra) are known to increase in the sera of patients with certain malignancies, including malignant lymphoma. This study aimed to assess the clinical significance of the sIL-2Ra level in non-Hodgkin’s lymphoma (NHL). We used ELISA to measure the sIL-2Ra levels in 48 newly diagnosed and untreated patients with NHL and evaluated the correlation between the sIL-2Ra levels and clinical characteristics and the International Prognostic Index (IPI). We monitored serum sIL-2Ra in 7 patients to compare the changes in their clinical progress with these levels. High levels of serum sIL-2Ra (≥2,000 U/mL) correlated well with parameters defining the high risk group according to the IPI, i.e., high tumor burden at diagnosis (stage III+IV) and lactate dehydrogenase ≥472 U/L. The levels were also associated with B symptoms, bone marrow involvement, and poor response to therapy. The sIL-2Ra level decreased during complete remission and was elevated during disease progression or relapse. A high level of sIL-2Ra was significantly associated with a low survival rate. These results suggest that serum sIL-2Ra might be useful as a biomarker for evaluating the prognosis of patients with NHL at the time of diagnosis and during therapy. A well-controlled, large-scale study is needed to clarify the clinical significance of sIL-2Ra in specific groups of NHL. (Korean J Lab Med 2010;30:600-5)
Abstract
Levels of soluble interleukin-2 receptor alpha (sIL-2Ra) are known to increase in the sera of patients with certain malignancies, including malignant lymphoma. This study aimed to assess the clinical significance of the sIL-2Ra level in non-Hodgkin’s lymphoma (NHL). We used ELISA to measure the sIL-2Ra levels in 48 newly diagnosed and untreated patients with NHL and evaluated the correlation between the sIL-2Ra levels and clinical characteristics and the International Prognostic Index (IPI). We monitored serum sIL-2Ra in 7 patients to compare the changes in their clinical progress with these levels. High levels of serum sIL-2Ra (≥2,000 U/mL) correlated well with parameters defining the high risk group according to the IPI, i.e., high tumor burden at diagnosis (stage III+IV) and lactate dehydrogenase ≥472 U/L. The levels were also associated with B symptoms, bone marrow involvement, and poor response to therapy. The sIL-2Ra level decreased during complete remission and was elevated during disease progression or relapse. A high level of sIL-2Ra was significantly associated with a low survival rate. These results suggest that serum sIL-2Ra might be useful as a biomarker for evaluating the prognosis of patients with NHL at the time of diagnosis and during therapy. A well-controlled, large-scale study is needed to clarify the clinical significance of sIL-2Ra in specific groups of NHL. (Korean J Lab Med 2010;30:600-5)
참고문헌 (17)
- Armitage JO, "New approach to classifying non-Hodgkin’s lymphomas: clinical features of the major histologic subtypes. Non-Hodgkin’s Lymphoma Classification Project", J Clin Oncol, 16, pp.2780~2795 (1998)
- Setoyama Y, "Usefulness of the measurement of serum soluble IL-2 receptor alpha chain levels in clinical monitoring of non-Hodgkin lymphoma", Rinsho Byori, 42, pp.834~842 (1994)
- A predictive model for aggressive non-Hodgkin’s lymphoma, "The International Non-Hodgkin's Lymphoma Prognostic Factors Project", N Engl J Med, 329, pp.987~994 (1993)
- Bien E, "Serum soluble interleukin 2 receptor alpha in human cancer of adults and children: a review", Biomarkers, 13, pp.1~26 (2008)
- Gandhi MK, "Plasma Epstein-Barr virus (EBV) DNA is a biomarker for EBV-positive Hodgkin’s lymphoma", Clinical Cancer Research, 12, pp.460~464 (2006)
- Rubin LA, "The molecular basis for the generation of the human soluble interleukin 2 receptor", Cytokine, 2, pp.330~336 (1990)
- Waldmann TA, "Anti-Tac (daclizumab, Zenapax) in the treatment of leukemia, autoimmune diseases, and in the prevention of allograft rejection: a 25-year personal odyssey", J Clin Immunol, 27, pp.1~18 (2007)
- Kitagawa JI, "Serum-soluble interleukin-2 receptor (sIL-2R) is an extremely strong prognostic factor for patients with peripheral T-cell lymphoma, unspecified (PTCL- U)", J Cancer Res Clin Oncol, 135, pp.53~59 (2009)
- Oki Y, "Prognostic value of serum soluble interleukin-2 receptor level in patients with diffuse large B cell lymphoma, treated with CHOPor RCHOP-based therapy", Leuk Lymphoma, 49, pp.1345~1351 (2008)
- Wakao D, "Serum thymidine kinase and soluble interleukin-2 receptor predict recurrence of malignant lymphoma", Ann Hematol, 81, pp.140~146 (2002)
- Goto H, "Serum-soluble interleukin-2 receptor (sIL-2R) level determines clinical outcome in patients with aggressive non-Hodgkin’s lymphoma: in combination with the International Prognostic Index", J Cancer Res Clin Oncol, 131, pp.73~79 (2005)
- Janik JE, "Elevated serum-soluble interleukin-2 receptor levels in patients with anaplastic large cell lymphoma", Blood, 104, pp.3355~3357 (2004)
- Yoshida S, "Serum concentrations of soluble interleukin-2 receptor in patients with malignant brain tumors", J Surg Oncol, 75, pp.131~135 (2000)
- Kaminska J, "Pretreatment serum levels of cytokines and cytokine receptors in patients with non-small cell lung cancer, and correlations with clinicopathological features and prognosis. M-CSF -an independent prognostic factor", Oncology, 70, pp.115~125 (2006)
- Witkowska AM, "On the role of sIL-2R measurements in rheumatoid arthritis and cancers", Mediators Inflamm, 2005, pp.121~130 (2005)
- Sakata H, "Serum soluble interleukin-2 receptor (IL-2R) and immunohistochemical staining of IL-2R", Tac antigen in colorectal cancer, 2002, pp.7, 312~317
- Huang A, "The presence of interleukin-2 receptor alpha in the serum of colorectal cancer patients is unlikely to result only from T cell up-regulat", Cancer Immunol Immunother, 51, pp.53~57 (2002)